Taysha Gene Therapies Expands Leadership Team with the Appointment of Chief Development Officer
May 13 2021 - 7:00AM
Business Wire
Mary Newman, former SVP of Regulatory Affairs
at Astellas Gene Therapies, joins Taysha with over 30 years of
experience in regulatory affairs and research and development in
the biotech industry
Extensive experience deeply rooted in gene
therapy at Astellas Gene Therapies, Audentes Therapeutics and
BioMarin
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced the most recent
addition to its leadership team with the appointment of industry
veteran Mary Newman as Chief Development Officer. Ms. Newman will
oversee program and portfolio management, as well as translational
sciences, and will report to Suyash Prasad, MBBS, M.Sc., MRCP,
MRCPCH, FFPM, Taysha’s Chief Medical Officer and Head of Research
and Development.
“We are pleased to welcome Mary to the Taysha leadership team,”
said RA Session II, President, Founder and CEO of Taysha. “In the
past few months, we have significantly expanded our extremely
talented R&D team, and Mary is an important addition to support
the achievement of our ambitious pipeline advancement goals. Her
decades of experience in all key aspects of drug development,
particularly in gene therapy and rare disease, will be invaluable
as we continue to grow our business.”
Ms. Newman joins Taysha with more than 30 years of experience in
regulatory affairs and research and development within the
biotechnology industry, focusing on rare diseases. Most recently,
she served as Senior Vice President of Regulatory Affairs at
Astellas Gene Therapies (formerly Audentes Therapeutics), where she
oversaw global regulatory strategic development, all primary
regulatory agency interactions, and regulatory compliance for
Audentes’ development candidates. Prior to joining Audentes, Ms.
Newman served as the Senior Vice President, Regulatory Affairs and
Quality Assurance at SARcode Bioscience Inc., and was responsible
for the development of Xiidra® for the treatment of dry eye
disease. The company was acquired by Shire Ltd. She previously held
various management positions, with increasing responsibility, in
Regulatory Affairs at BioMarin Pharmaceutical, Inc., Berlex Inc.
(now Bayer HealthCare Pharmaceuticals Inc.), and Sequus
Pharmaceuticals, Inc. (now Johnson & Johnson). While at
BioMarin, Ms. Newman oversaw the development and approval of Kuvan®
for the treatment of phenylketonuria (PKU), Naglazyme® for
mucopolysaccharidosis (MPS) VI, and supported the final approval of
Aldurazyme® for MPS I. She has also held various research and
development leadership roles in oncology, neurology, and antifungal
therapeutic areas. Ms. Newman serves as a member of the board of
directors of Vedere Bio and is an advisor to the board of directors
of Chameleon Biosciences. Ms. Newman holds a B.S. in Physiology
from Oregon State University.
“I am excited to join Taysha at such a transformative time in
the company’s corporate lifecycle,” said Ms. Newman. “Taysha is
well-positioned to be a leader in developing disease-modifying gene
therapies for patients with monogenic CNS diseases. I look forward
to contributing to the further progression of the company’s robust
pipeline of promising drug candidates.”
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210513005355/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com Media Contact: Carolyn Hawley Canale
Communications carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Sep 2023 to Sep 2024